Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of autologous tumor lysate particle-loaded dendritic cell vaccination in combination with systemic therapies in patients with recurrent and metastatic melanoma.
Adams AM, Chick RC, Vreeland TJ, Clifton GT, Hale DF, McCarthy PM, O'Shea AE, Bohan PMK, Hickerson AT, Park H, Sloan AJ, Hyngstrom J, Berger AC, Jakub JW, Sussman JJ, Shaheen M, Wagner T, Faries MB, Peoples GE. Adams AM, et al. Among authors: hale df. Melanoma Res. 2021 Aug 1;31(4):378-388. doi: 10.1097/CMR.0000000000000758. Melanoma Res. 2021. PMID: 34193804
A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2.
Greene JM, Schneble EJ, Jackson DO, Hale DF, Vreeland TJ, Flores M, Martin J, Herbert GS, Hardin MO, Yu X, Wagner TE, Peoples GE. Greene JM, et al. Among authors: hale df. Cancer Immunol Immunother. 2016 Apr;65(4):383-92. doi: 10.1007/s00262-016-1809-6. Epub 2016 Feb 19. Cancer Immunol Immunother. 2016. PMID: 26894495 Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: hale df. Ann Oncol. 2016 Jul;27(7):1241-8. doi: 10.1093/annonc/mdw150. Epub 2016 Mar 30. Ann Oncol. 2016. PMID: 27029708 Free PMC article. Clinical Trial.
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence.
Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, Perez SA, Ponniah S, Baxevanis CN, Papamichail M, Peoples GE. Mittendorf EA, et al. Among authors: hale df. Oncotarget. 2016 Oct 4;7(40):66192-66201. doi: 10.18632/oncotarget.11751. Oncotarget. 2016. PMID: 27589688 Free PMC article. Clinical Trial.
Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients.
Jackson DO, Byrd K, Vreeland TJ, Hale DF, Herbert GS, Greene JM, Schneble EJ, Berry JS, Trappey AF, Clifton GT, Hardin MO, Martin J, Elkas JC, Conrads TP, Darcy KM, Hamilton CA, Maxwell GL, Peoples GE. Jackson DO, et al. Among authors: hale df. Oncotarget. 2017 Feb 28;8(9):15912-15923. doi: 10.18632/oncotarget.13305. Oncotarget. 2017. PMID: 27852036 Free PMC article. Clinical Trial.
38 results